Atlas Bio raises $10M to run in silico clinical trials with AI

The company's website describes simulated cohorts in asthma, atopic dermatitis, ulcerative colitis and alopecia areata. In atopic dermatitis, Atlas said it predicted that an MRGPRX2 inhibitor would miss its endpoint, and that a later Phase II readout confirmed the miss. The customer was not named. Atlas said detailed methods and readouts are available only under a nondisclosure agreement, which means outsiders cannot check the work.

In ulcerative colitis, the company said it simulated a PD-1 depleting antibody across 163 patient profiles and predicted remission of up to 53.4%.

Creandum's post went further. It said Atlas is under contract with a top-10 global pharmaceutical company and in talks with more than a dozen of the largest drugmakers, and that "every prospective prediction made on real trial outcomes has proven correct." Those are claims from an investor with a stake in the outcome. No customer has confirmed them publicly.

Valuation and backers

Handelsblatt reported on Oct. 28, 2026, that the company is valued at $60 million, and said angel investors include the founders of Black Forest Labs and Chai Discovery. An aggregator cited a post-money valuation of roughly $100 million, attributing it to TechCrunch, but that report could not be located. Neither figure has been confirmed by the company in the materials reviewed.

Katharina Wilhelm, a Creandum partner, wrote: "We're proud to be leading Atlas Bio's $11m Seed round." AI4S.fyi and Sesamers said she joins the board. Dealroom ranked the seed in the 98th percentile for Swiss big data seed rounds.

The team and what comes next

Romanski previously led machine learning teams at understand.ai. Chief technology officer Sebastian Bayer led large language model research at Google, according to the company's website. Dominik Hartl, the chief scientific officer, built an indication-selection framework at Idorsia, and chief commercial officer Malcolm Fogarty previously worked at Lindus Health, GSK and Haleon.

Atlas was founded in 2024 and registered as Atlas Bio AG in Basel on July 30 of that year. As of Oct. 28, 2026, LinkedIn lists 11 to 50 employees. According to Sesamers, the new money will fund hiring of scientific and commercial staff and deeper validation of the platform, and will help bring on more enterprise customers through 2026.

A crowded field, and a hard problem

Atlas is not alone. Unlearn, which builds digital twins for clinical trials, raised a $50 million Series C in February 2024, according to Dealroom. QuantHealth, another trial-simulation company, announced a $45 million Series B led by Qumra Capital. Both figures are drawn from the reporting reviewed, and readers should check for later rounds.

Atlas is aiming at Phase II, the stage where drug candidates fail most often. A BIO analysis covering 2006 to 2015, now an older benchmark, found that 30.7% of drugs moved from Phase II to Phase III. Regulators are also showing interest in alternatives to traditional testing: the FDA has issued draft guidance on new approach methodologies, a category that includes in silico modeling.

Romanski told Handelsblatt that the decisive question is no longer whether good molecules can be found, but how quickly their efficacy can be proven in clinical trials. Atlas said its first trial results are due within six weeks of the announcement, which will offer the first public test of that argument.